Tumor Immunology Flashcards
Carcinoma
epithelial cells
most common cancers
Sarcomas
muscle cells, fat cells or fibroblasts
lymphoma
solid tumors of lymphoid tissue
leukemias
lymphocytes and other hematopoetic cells
benign tumors
slow growth rate
somewhat differentiated cells
usually encapsulated, so they don’t spread
not normally fatal unless they are in specific spots
malignant tumors
undifferentiated cells
readily metastasize
fatal if untreated
TSAs
antigens unique to a particular tumor and not present on normal cells types
very common in animals, but not often seen in humans
good target for immune response
TAAs
antigens shared by different tumors, also found on normal tissues
can be useful for diagnosis, but not so much for treatment
oncofetal antigens
expressed on fetal, but not adult tissues
alpha fetal proteins (AFP)
produced by certain liver cancers
carcinoembryonic antigen (CEA)
increased in colon cancer and smokers
oncogenic viral antigens
happens with some RNA/DNA viruses
makes tumors easy for immune system to deal with because they are seen as foreign
Differentation antigens
tissue specific antigens
good for diagnosis, but not so much for treatment
antibodies
super weak sauce
don’t help
some times actually hurt
CTLs
most effective against virus induced tumors
NK cells
help against tumors of hematopoetic origin and those that are virus induced activating signal is a down-regulation of class I MHC their effect is enhanced by interferons, TNF-alpha, and IL-2
Lymphokine-activated killer (LAK) cells
enhanced killing of various tumors and broadened tumor recognition capability
Macrophage
kill tumor cells by ADCC or by release of TNF-alpha
TNF
can directly lyse tumor cells possibly by producing free radicals or by causing hemorrhagic necrosis of the tumor blood vessels
Examples of tumor evasion strategies
don’t express MHC proteins
anti-tumor antibodies may act as blocking factors
antigens shed by tumor cells bind to cell surface receptors
tumor antigens masked by mucopolysacchardes
tumor releases immunosuppressive suvstances
creating an immunoprivileged site by encasing themselves in collagen and fibrin
Treatment by antibodies to surface immunoglobulin of B cell lymphomas
cell lysis by ADCC or complement required to decrease tumor burden
outgrowth of tumor cell mutants are a problem
Herceptin
targets HER-2/neu growth factor receptor
blocks receptor/ligand interaction
Immunoconjugates
antibodies coupled to a toxic substance
conjugate must be endocytoses
F(ab’)2 fragments (no Fc regions) used to avoid non-specific binding
Bi-specific antiodies
genetically-engineered antibodies that recognize tumor antigens and immune system cells